Compare Eli Lilly And Co (LLY) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Yum China Holdings Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Yum China Holdings Inc trades at $42.92 (market cap $14.11B). The key difference: Eli Lilly And Co is far larger — about 73.7× Yum China Holdings Inc's market cap, and Yum China Holdings Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Yum China Holdings Inc for 77 Days on average.
| LLY | YUMC | |
|---|---|---|
Market Cap | $1.04T | $14.11B |
Volume | 3,064,878 | 2,350,650 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.28K | $57.95 |
52-Week Low | $799.57 | $39.98 |
Typical Hold Time | 93 Days | 77 Days |
Enterprise Value | $1.09T | $15.02B |
Dividend Yield | 0.59% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
YUMC trades at $42.92, up 5.58% today, with strong analyst support (73.68% buy ratings) but technical indicators show bearish momentum. The company demonstrates solid fundamentals with consistent revenue growth from $9.6B in 2022 to $11.8B in 2025, and net income improving to $929M. Recent strategic moves include the $1.2B acquisition of Pizza Hut China brand ownership and expansion of Pizza Hut Burger Bars to 300 locations.
YUMC presents a value opportunity with reasonable valuation (P/E 15.3, P/S 1.2) and strong profitability (ROE 17.5%), though technical weakness and China economic exposure pose near-term risks. The stock's 25.6% analyst upside potential and consistent earnings beats support long-term growth prospects despite current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
